We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioFocus Extends Collaboration with Amgen into 2012
News

BioFocus Extends Collaboration with Amgen into 2012

BioFocus Extends Collaboration with Amgen into 2012
News

BioFocus Extends Collaboration with Amgen into 2012

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioFocus Extends Collaboration with Amgen into 2012"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under the terms of the extended agreement, BioFocus will receive €2.0 M ($2.6 M) in research fees for the first year. Additionally, BioFocus is eligible to receive payments of access fees and success-based milestones.

The collaboration, which was initiated in 2002 and extended in 2006 and again in 2008, involves the identification of new molecules against various drug targets. Starting in 2011, the collaboration will involve the addition of BioFocus’ unique target discovery platform to deliver novel targets to support Amgen’s therapeutic programs.

“We are pleased to have delivered well in our long-standing collaboration with Amgen, resulting in an extension for the third time,” said Dr. Chris Newton, Senior VP Galapagos Services. “With each extension, Amgen has expanded the range of services provided by BioFocus, with target discovery being included this time around. We are very proud to win this opportunity to deliver high quality, innovative modes of action to Amgen.”

Advertisement